Skip to content
OpenCapital
Get started

TG Therapeutics TGTX Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$204.9MBeat by $4.6M
EPS$0.17Miss by $0.06
Revenue estimate$200.3M
EPS estimate$0.23

Next report

Aug 3, 2026 (In 5 days)
Revenue estimate$229.8M
EPS estimate$0.31

Financials

Q1 2026

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$8.53B+49.4%
Enterprise value$8.85B+51.5%
P/E18.5×-76.0×
P/S12.2×-0.4×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Versus estimates

Revenue

Q1 2026$204.9MBeat by $4.6M
Q4 2025$192.6MBeat by $785.5KQ3 2025$161.7MMiss by $32.1MQ2 2025$141.1MMiss by $5.1MQ1 2025$120.9MMiss by $13.3MQ4 2024$108.2MMiss by $615.0K

Diluted EPS

Q1 2026$0.17Miss by $0.06
Q4 2025$0.14Miss by $0.21Q3 2025$2.43Beat by $2.19Q2 2025$0.17Miss by $0.15Q1 2025$0.03Miss by $0.15Q4 2024$0.15Beat by $0.07

Ask the moment TG Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did TG Therapeutics report Q1 2026 earnings?
TG Therapeutics (TGTX) reported Q1 2026 earnings on May 6, 2026 before market open.
What were TG Therapeutics's Q1 2026 revenue and EPS?
TG Therapeutics reported revenue of $204.9M and eps of $0.17 for Q1 2026.
Did TG Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $200.3M by $4.6M. EPS missed the consensus estimate of $0.23 by $0.06.
How did TG Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 69.6% from $120.9M a year earlier and eps grew 466.7% from $0.03.
Where can I find TG Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-015013) and the 10-Q periodic report (0001437749-26-015246) directly on SEC EDGAR. The filing index links above go to sec.gov.